I've watched talented teams burn through six-figure pipeline budgets in healthtech without ever getting to the real question not how to go to market, but whether they actually understood the market they were entering.
They had decks. They had ICPs. They had a sales motion, a content calendar, a series of "aligned" stakeholders. They had everything except the one thing that matters: a ruthlessly honest answer to who this is for and why they would actually change.
That's where most GTM strategies die, before the first sales call, before the first campaign, before anyone realizes the engine is pointed in the wrong direction.
The Three Upstream Failures
Most post-mortems in healthtech point to execution. The reps weren't trained. The messaging didn't land. The product wasn't ready. These are real, but they're symptoms. The disease is upstream, and it almost always traces back to three things.
First: The ICP isn't real.
I don't mean it wasn't documented. I mean it wasn't validated against how buyers actually behave. There's a version of ICP work that lives entirely inside a conference room, driven by revenue ambition rather than market reality. The team asks, "Who should buy this?" instead of "Who does buy this, and what drove them to change?" Those are different questions. One produces a wishlist. The other produces a go-to-market.
In healthtech, this is especially dangerous. The economic buyer is often not the end user. The champion has no budget authority. The budget holder has never actually used the product. You can have a beautifully articulated persona that maps to exactly zero real buying decisions because it conflated three different people into one fictional stakeholder. The result is messaging that resonates with no one and a motion that stalls at every stage.
Second: Positioning was assumed, not tested.
Positioning isn't a tagline. It's not a value prop statement. It's the specific frame you've claimed in the mind of a buyer who already has beliefs, biases, and existing relationships. If you don't understand what they already believe, and what it would cost them to change, your positioning is just noise.
The question isn't what do we want them to think? It's what do they already think, and how does our story fit into or challenge that?
Most teams skip this. They build positioning in isolation and push it into the market hoping it sticks. In healthcare where trust is slow, switching costs are real, and procurement cycles can span quarters, hope is not a strategy. By the time you realize the message isn't landing, you've lost the window.
Third: Sequencing was backwards.
This one is quieter but just as lethal. Teams pick their channels before they've confirmed their motion. They invest in demand gen before they have proof points. They build outbound sequences before they've had ten real discovery conversations that actually converted.
Speed kills here. Not because moving fast is wrong, but because moving fast in the wrong direction multiplies the cost of being wrong. Every sprint compounds the misalignment. Every campaign solidifies positioning that hasn't been tested. Every new hire inherits a motion that was never validated.
By the time the data catches up, pipeline stalls, conversion rates plateau, reps start discounting to close. The organization has scar tissue. Now you're not just fixing the strategy. You're unlearning habits, resetting narratives, and rebuilding trust with a market that got mixed signals from the start.
What Disciplined GTM Actually Looks Like
It's not a framework. Frameworks give people something to present. What I'm describing is a way of thinking, a set of honest questions asked in the right order, held long enough to produce real answers.
It starts with humility about what you don't know. Not performative humility, operational humility. The willingness to delay a campaign launch because you haven't yet confirmed the problem the buyer is actually trying to solve. The willingness to kill a channel that's generating volume but no qualified pipeline. The discipline to treat early signal as data, not confirmation.
In practice, this means front-loading the uncomfortable conversations. Talking to buyers who said no. Understanding what they're already doing, and why stopping is harder than it looks. Getting clear on where you actually sit in the category, not where you'd like to sit. Because in healthtech, category definition isn't a marketing exercise. It's a survival skill.
Healthcare is not a monolith. It is a dense, fragmented system of incentives, regulations, relationships, and deeply entrenched workflows. When you go to market here, you're not just competing with other vendors, you're competing with inertia, with "we built it ourselves," with procurement committees that add months to every deal, with compliance requirements that reshape your buying journey before you even get to value.
That means your category definition has to do real work. It has to create a frame that makes your buyer feel the cost of the status quo not just the value of the solution. And it has to be precise enough that the right person hears it and thinks, that's exactly the problem I have, rather than nodding politely and moving on.
The Real Cost of Getting It Wrong
Pipeline burned is recoverable. Time is not.
The healthtech companies that win don't necessarily move the fastest. They move with the most clarity, about who they're for, what problem they actually solve, and what it takes to unseat the current answer. That clarity is earned, not assumed. It comes from hard upstream questions asked before the motion is built, not after it's failed.
Most teams never get there. They confuse activity for progress, momentum for strategy, and a full calendar for a working go-to-market.
The companies that get it right slow down long enough to ask the questions everyone else is too busy to answer. Then they move, and they don't look back.